Senti Biosciences (SNTI) Non Operating Income (2021 - 2025)
Senti Biosciences' quarterly Non Operating Income came in at $200000.0 in Q4 2025, down 2.91% year-on-year from $206000.0 in Q4 2024, and up 116.98% quarter-over-quarter from -$1.2 million in Q3 2025.
Senti Biosciences has reported Non Operating Income for 5 years, with the latest figure at $200000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income fell 2.91% year-over-year to $200000.0; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (up 540.3% YoY), and the FY2025 full-year result was $800000.0, up 300.0% from the prior year.
- Non Operating Income for Q4 2025 stood at $200000.0, up from -$1.2 million in the prior quarter.
- The five-year high for Non Operating Income was $7.3 million in Q3 2023, with the low at -$3.0 million in Q2 2021.
- Average Non Operating Income over 5 years is $380000.0, with a median of $8000.0 recorded in 2023.
- Year-over-year, Non Operating Income soared 362950.0% in 2023 and plunged 10609.09% in 2025.
- Tracing SNTI's Non Operating Income over 5 years: stood at -$10000.0 in 2021, then surged by 60.0% to -$4000.0 in 2022, then jumped by 350.0% to $10000.0 in 2023, then jumped by 1960.0% to $206000.0 in 2024, then retreated by 2.91% to $200000.0 in 2025.
- The last three Non Operating Income figures came in at $200000.0 (Q4 2025), -$1.2 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | -1.18 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 206,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Sep 30, 2023 | 7.26 Mn |
| Jun 30, 2023 | -4,000.00 |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 25,000.00 |
| Mar 31, 2022 | -50,000.00 |
| Dec 31, 2021 | -10,000.00 |
| Sep 30, 2021 | 21,000.00 |
| Jun 30, 2021 | -3.01 Mn |